HealthOptions.com
About HealthOptions.com
On December 17, 2004, the drug giant Pfizer revealed that patients taking Celebrex in a long-term cancer-prevention trial had more than twice the number of fatal or non-fatal heart attacks compared with those taking a placebo. Another trial showed no increased risk. Dr. Marie Griffin, an epidemiologist and drug safety expert at Vanderbilt University, said the new findings on Celebrex is worrisome evidence suggesting that all these COX-2 drugs have similar risks.
